Unlike many biotech startups reliant on venture capital, Vivtex pursued a different path. By securing around 10 early pharma collaborations, the company generated a substantial stream of non-dilutive revenue, achieving profitability and financial independence far earlier than is typical.

Lacking capital, Derek Small was forced to personally write grants and lead regulatory affairs. This hands-on, "virtual company" approach, born of necessity, gave him a profound, holistic understanding of the science and operations he wouldn't have gained otherwise.

Vivtex funded its growth and reached profitability not through traditional VC rounds, but by securing around 10 early pharma partnerships. This strategy provided significant non-dilutive revenue, reducing their reliance on investors and giving them more control over their trajectory—a powerful alternative to the typical biotech funding model.

MRM Health's founder, Sam Possemiers, leveraged his profitable Contract Research Organization (CRO), Prodigest, to finance the entire seed stage of his new biotech venture. Reinvesting proceeds into technology development allowed MRM to de-risk its platform for five years without taking on early-stage dilutive funding.

By deliberately not over-raising, biotech startups preserve M&A optionality. A seemingly modest exit, like Surf Bio's $400M acquisition, can be a massive win for founders and early investors if the company remained lean, avoiding the need for a billion-dollar outcome.

Midjourney's financial independence from venture capital gives its founder, David Holz, the freedom to pursue ambitious, capital-intensive hardware projects. This kind of bold, non-adjacent expansion is rarely possible for VC-backed startups who are locked into a cycle of hitting specific KPIs to secure their next funding round.

Repro Novo's co-founders invested their own money for the costly process of finding and negotiating assets. This allowed them to secure a promising candidate before approaching institutional investors, demonstrating strong conviction and de-risking the initial investment for VCs.

For small biotechs, the playbook for success extends beyond scientific discovery. It requires creativity and innovation in the operational process itself—finding efficient paths through regulatory checkpoints, securing non-traditional funding, and leveraging external resources to advance development with limited capital.

Venture capital can create a "treadmill" of raising rounds based on specific metrics, not building a sustainable business. Avoiding VC funding allowed Donald Spann to maintain control, focus on long-term viability, and build a company he could sustain without external pressures or risks.